Analysts Set Expectations for REVB Q1 Earnings

Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) – Analysts at Zacks Research issued their Q1 2027 earnings per share (EPS) estimates for shares of Revelation Biosciences in a research report issued to clients and investors on Friday, November 6th. Zacks Research analyst B. Sorensen anticipates that the company will post earnings of ($4.71) per share for the quarter. The consensus estimate for Revelation Biosciences’ current full-year earnings is ($24.53) per share. Zacks Research also issued estimates for Revelation Biosciences’ Q2 2027 earnings at ($4.10) EPS, Q3 2027 earnings at ($4.05) EPS and Q4 2027 earnings at ($4.92) EPS.

Revelation Biosciences (NASDAQ:REVB – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($5.92) earnings per share for the quarter, topping the consensus estimate of ($6.16) by $0.24.

Separately, Weiss Ratings upgraded shares of Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the company has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on Revelation Biosciences

Revelation Biosciences Price Performance

Shares of NASDAQ:REVB opened at $4.33 on Thursday. The business has a fifty day moving average price of $5.16 and a 200-day moving average price of $7.42. The company has a market capitalization of $2.95 million, a PE ratio of -0.10 and a beta of -0.13. Revelation Biosciences has a 1-year low of $3.08 and a 1-year high of $40.60.

About Revelation Biosciences

(Get Free Report)

Revelation Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases. Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.

Featured Articles

Earnings History and Estimates for Revelation Biosciences (NASDAQ:REVB)

Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.